LOGIN  |  REGISTER
Astria Therapeutics
Assertio

Veradigm Practice Management Ranks First in Practice Management Solutions from Black Book™ Research

March 14, 2023 | Last Trade: US$9.10 2.29 33.63

CHICAGO / Mar 14, 2023 / Business Wire / Veradigm® (NASDAQ: MDRX), a leading provider of healthcare data and technology solutions, announced today that Black Book, a healthcare-centric market research and public opinion research and consulting company, has ranked Veradigm Practice Management first for its 2023 Practice Management Solutions, 50+ Physician Groups category.

Veradigm Practice Management placed in the top five practice management solutions across all physician group size categories, including:

  • #1 in 50+ Physician Groups
  • #3 in 10-49 Physician Groups
  • #4 in 4-9 Physician Groups
  • #3 in 1-3 Physician Groups

Veradigm Practice Management is a comprehensive revenue cycle management solution for physician practices of all sizes and specialties. With over 20 years’ experience, Veradigm Practice Management is an EHR-agnostic solution that streamlines every step along the revenue cycle, from pre-appointment to final collections and data analysis.

“With best-in-class solutions like Veradigm Practice Management, we are supporting healthcare providers to optimize revenue, manage their day-to-day operations, engage in productive patient interactions, and save staff time,” said Tom Langan, President and Chief Commercial Officer of Veradigm. “This ranking demonstrates our continued commitment to help deliver a higher quality of care, more economically.”

About Veradigm®

Veradigm is a healthcare technology company that drives value through its unique combination of platforms, data, expertise, connectivity, and scale. The Veradigm Network features a dynamic community of solutions and partners providing advanced insights, technology, and data-driven solutions, all working together to transform healthcare insightfully. For more information on Veradigm, visit http://www.veradigm.com, or find Veradigm on LinkedIn, Facebook, Twitter, and YouTube

© 2023 Veradigm LLC and/or its affiliates. All rights reserved. Cited marks are the property of Veradigm LLC and/or its affiliates. All other product or company names are the property of their respective holders, all rights reserved.

Chimerix

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB